1. Home
  2. NTLA
  3. NTLA News

Latest Intellia Therapeutics Inc. (NTLA) News on April 19, 2025

Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple
NTLA

Insider Monkey

10 days ago

Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple

Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN
NTLA

Clinical Trials Arena

15 days ago

Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NTLA

GlobeNewswire

16 days ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IO360 Summit: Improving CAR-T cell therapy manufacture and accessibility
NTLA

Pharmaceutical Technology

16 days ago

IO360 Summit: Improving CAR-T cell therapy manufacture and accessibility

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy
NTLA

GlobeNewswire

16 days ago

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

NTLA

MT Newswires

16 days ago

RBC Cuts Price Target on Intellia Therapeutics to $32 From $37, Keeps Outperform, Speculative Risk

Is Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy?
NTLA

Insider Monkey

18 days ago

Is Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy?

Biotech stocks slide as Marks resignation seen being negative for sector
NTLA

TipRanks

18 days ago

Biotech stocks slide as Marks resignation seen being negative for sector

Intellia Focuses on Pipeline Development Amid Stiff Competition
NTLA

Zacks

19 days ago

Intellia Focuses on Pipeline Development Amid Stiff Competition

NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication
NTLA

Zacks

23 days ago

NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication

NTLA

MT Newswires

24 days ago

Intellia Therapeutics' Gene-Editing Drug Gets FDA Designation

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
NTLA

GlobeNewswire

24 days ago

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
NTLA

Motley Fool

a month ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Royal Caribbean upgraded, AppLovin downgraded: Wall Street's top analyst calls
NTLA

The Fly

a month ago

Royal Caribbean upgraded, AppLovin downgraded: Wall Street's top analyst calls

NTLA

MT Newswires

a month ago

HC Wainwright Initiates Intellia Therapeutics at Buy With $30 Price Target

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NTLA

GlobeNewswire

2 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NTLA

MT Newswires

2 months ago

Truist Securities Adjusts Intellia Therapeutics Price Target to $50 From $90, Maintains Buy Rating

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
NTLA

Simply Wall St.

2 months ago

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

NTLA's Q4 Loss Narrower Than Estimates, Revenues Increase Y/Y
NTLA

Zacks

2 months ago

NTLA's Q4 Loss Narrower Than Estimates, Revenues Increase Y/Y

Intellia Therapeutics Full Year 2024 Earnings: Beats Expectations
NTLA

Simply Wall St.

2 months ago

Intellia Therapeutics Full Year 2024 Earnings: Beats Expectations

NTLA

MT Newswires

2 months ago

RBC Cuts Price Target on Intellia Therapeutics to $37 From $47, Keeps Outperform, Speculative Risk

NTLA

MT Newswires

2 months ago

JPMorgan Downgrades Intellia Therapeutics to Neutral, Price Target is $13

NTLA

Morningstar Research

2 months ago

Analyst Report: Intellia Therapeutics, Inc.

Intellia Therapeutics Inc (NTLA) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...
NTLA

GuruFocus.com

2 months ago

Intellia Therapeutics Inc (NTLA) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...

NTLA

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Intellia Therapeutics Inc Earnings Call

NTLA

MT Newswires

2 months ago

Intellia Therapeutics Q4 Net Loss Narrows; Shares Rise Pre-Bell

Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates
NTLA

Zacks

2 months ago

Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress
NTLA

GlobeNewswire

2 months ago

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
NTLA

Zacks

2 months ago

Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

What's in Store for These 5 Biotech Stocks This Earnings Season?
NTLA

Zacks

2 months ago

What's in Store for These 5 Biotech Stocks This Earnings Season?

2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street
NTLA

Motley Fool

2 months ago

2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
NTLA

Zacks

2 months ago

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Intellia Therapeutics (NTLA) Stock Jumps 6.5%: Will It Continue to Soar?
NTLA

Zacks

2 months ago

Intellia Therapeutics (NTLA) Stock Jumps 6.5%: Will It Continue to Soar?

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates
NTLA

GlobeNewswire

2 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates

Intellia Therapeutics (NTLA): Among The Small–Cap Stocks Insiders Are Selling Recently
NTLA

Insider Monkey

2 months ago

Intellia Therapeutics (NTLA): Among The Small–Cap Stocks Insiders Are Selling Recently

Does Intellia Therapeutics (NTLA) Have the Potential to Rally 422.41% as Wall Street Analysts Expect?
NTLA

Zacks

2 months ago

Does Intellia Therapeutics (NTLA) Have the Potential to Rally 422.41% as Wall Street Analysts Expect?

Intellia Therapeutics Inc. (NTLA): Among Cathie Wood’s Top Stock Picks for 2025
NTLA

Insider Monkey

2 months ago

Intellia Therapeutics Inc. (NTLA): Among Cathie Wood’s Top Stock Picks for 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NTLA

GlobeNewswire

2 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NTLA

MT Newswires

3 months ago

Intellia Therapeutics Shares Fall After Morgan Stanley Downgrade

NTLA

MT Newswires

3 months ago

Update: Morgan Stanley Downgrades Intellia Therapeutics to Equal Weight From Overweight, Cuts Price Target to $11 From $56

NTLA

MT Newswires

3 months ago

Morgan Stanley Downgrades Intellia Therapeutics to Equal Weight From Overweight, $56 Price Target

Intellia doses first subject in trial of NTLA-2002 for hereditary angioedema
NTLA

Clinical Trials Arena

3 months ago

Intellia doses first subject in trial of NTLA-2002 for hereditary angioedema

NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate
NTLA

Zacks

3 months ago

NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate

NTLA

MT Newswires

3 months ago

Intellia Doses First Patient in Phase 3 Trial of Potential Treatment for Hereditary Angioedema

Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema
NTLA

GlobeNewswire

3 months ago

Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema

Intellia makes progress on HAE study; 2 more China drug deals
NTLA

BioPharma Dive

3 months ago

Intellia makes progress on HAE study; 2 more China drug deals

Intellia Loses 21.6% in a Week: How Should You Play the Stock?
NTLA

Zacks

3 months ago

Intellia Loses 21.6% in a Week: How Should You Play the Stock?

The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK
NTLA

Zacks

3 months ago

The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK

Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates
NTLA

Zacks

3 months ago

Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates

Intellia slashes workforce by 27% to focus on late stage CRISPR candidates
NTLA

Pharmaceutical Technology

3 months ago

Intellia slashes workforce by 27% to focus on late stage CRISPR candidates

Intellia Therapeutics price target lowered to $50 from $70 at BMO Capital
NTLA

TipRanks

3 months ago

Intellia Therapeutics price target lowered to $50 from $70 at BMO Capital

Intellia Therapeutics price target lowered to $60 from $70 at Wells Fargo
NTLA

TipRanks

3 months ago

Intellia Therapeutics price target lowered to $60 from $70 at Wells Fargo

Why Is Intellia Therapeutics Stock Trading Lower On Friday?
NTLA

Benzinga

3 months ago

Why Is Intellia Therapeutics Stock Trading Lower On Friday?

NTLA Announces Strategic Reorganization & Job Cuts in 2025, Stock Down
NTLA

Zacks

3 months ago

NTLA Announces Strategic Reorganization & Job Cuts in 2025, Stock Down

Intellia to stop work on rare disease therapy, lay off staff
NTLA

BioPharma Dive

3 months ago

Intellia to stop work on rare disease therapy, lay off staff

NTLA

MT Newswires

3 months ago

Intellia Therapeutics to Workforce by 27%, Halt Some Programs

Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)
NTLA

GlobeNewswire

3 months ago

Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)

NTLA

MT Newswires

3 months ago

BofA Securities Adjusts Price Target on Intellia Therapeutics to $50 From $58, Maintains Buy Rating

NTLA

MT Newswires

3 months ago

RBC Cuts Price Target on Intellia Therapeutics to $47 From $54, Keeps Outperform, Speculative Risk

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NTLA

GlobeNewswire

3 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Why Is Intellia Therapeutics, Inc. (NTLA) Among the Top CRISPR Stocks to Invest In?
NTLA

Insider Monkey

4 months ago

Why Is Intellia Therapeutics, Inc. (NTLA) Among the Top CRISPR Stocks to Invest In?

Intellia Therapeutics, Inc. (NTLA): Is This Gene Therapy Stock a Good Buy Right Now?
NTLA

Insider Monkey

4 months ago

Intellia Therapeutics, Inc. (NTLA): Is This Gene Therapy Stock a Good Buy Right Now?

Here's Why We're Watching Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Situation
NTLA

Simply Wall St.

4 months ago

Here's Why We're Watching Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Situation

Intellia Crashes 60% in a Year: How Should You Play the Stock?
NTLA

Zacks

4 months ago

Intellia Crashes 60% in a Year: How Should You Play the Stock?

Why Intellia Therapeutics (NTLA) Is the Worst ARK Stock to Buy According to Short Sellers
NTLA

Insider Monkey

4 months ago

Why Intellia Therapeutics (NTLA) Is the Worst ARK Stock to Buy According to Short Sellers

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NTLA

GlobeNewswire

5 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy
NTLA

Zacks

5 months ago

NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy

BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug
NTLA

Investor's Business Daily

5 months ago

BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug

NTLA

MT Newswires

5 months ago

Sector Update: Health Care Stocks Rise in Monday Afternoon Trading

NTLA

MT Newswires

5 months ago

Intellia Therapeutics' Nex-z Receives FDA Regenerative Medicine Advanced Therapy Designation

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
NTLA

GlobeNewswire

5 months ago

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?
NTLA

Motley Fool

5 months ago

Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?

Intellia Therapeutics Announces Promising CRISPR Therapy Results
NTLA

TipRanks

5 months ago

Intellia Therapeutics Announces Promising CRISPR Therapy Results

ReCode to secure funds for cystic fibrosis gene correction treatments
NTLA

Pharmaceutical Technology

5 months ago

ReCode to secure funds for cystic fibrosis gene correction treatments

Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo
NTLA

TipRanks

5 months ago

Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo

Intellia’s gene editing therapy shows early potential in rare heart condition
NTLA

Clinical Trials Arena

5 months ago

Intellia’s gene editing therapy shows early potential in rare heart condition

CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest
NTLA

BioPharma Dive

5 months ago

CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
NTLA

GlobeNewswire

5 months ago

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

NTLA

Morningstar Research

5 months ago

Analyst Report: Intellia Therapeutics, Inc.

NTLA

Morningstar Research

5 months ago

Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

NTLA

MT Newswires

5 months ago

Truist Securities Cuts Price Target on Intellia Therapeutics to $90 From $120, Maintains Buy Rating

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates
NTLA

Simply Wall St.

5 months ago

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates

Intellia Therapeutics Inc (NTLA) Q3 2024 Earnings Call Highlights: Financial Stability and ...
NTLA

GuruFocus.com

5 months ago

Intellia Therapeutics Inc (NTLA) Q3 2024 Earnings Call Highlights: Financial Stability and ...

NTLA's Q3 Earnings & Revenues Beat Estimates, Pipeline in Focus
NTLA

Zacks

5 months ago

NTLA's Q3 Earnings & Revenues Beat Estimates, Pipeline in Focus

Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Tops Revenue Estimates
NTLA

Zacks

5 months ago

Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Tops Revenue Estimates

Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
NTLA

GlobeNewswire

5 months ago

Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day?
NTLA

Motley Fool

5 months ago

Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day?

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NTLA

GlobeNewswire

5 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Immatics (IMTX) Expected to Beat Earnings Estimates: Should You Buy?
NTLA

Zacks

5 months ago

Immatics (IMTX) Expected to Beat Earnings Estimates: Should You Buy?

This Beaten-Down Stock Could Soar by 354%, According to Wall Street
NTLA

Motley Fool

5 months ago

This Beaten-Down Stock Could Soar by 354%, According to Wall Street

Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024
NTLA

GlobeNewswire

6 months ago

Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024

Intellia Therapeutics (NTLA): Promising Gene Editing Stock with CRISPR-Cas9 Therapies
NTLA

Insider Monkey

6 months ago

Intellia Therapeutics (NTLA): Promising Gene Editing Stock with CRISPR-Cas9 Therapies

Intellia Therapeutics Advances with Promising Phase 2 Results
NTLA

TipRanks

6 months ago

Intellia Therapeutics Advances with Promising Phase 2 Results

Intellia reports positive data from Phase II study of NTLA-2002 for HAE
NTLA

Clinical Trials Arena

6 months ago

Intellia reports positive data from Phase II study of NTLA-2002 for HAE

NTLA

Morningstar Research

6 months ago

Analyst Report: Intellia Therapeutics, Inc.

Why Intellia Therapeutics Stock Plummeted by 20% Today
NTLA

Motley Fool

6 months ago

Why Intellia Therapeutics Stock Plummeted by 20% Today

Intellia's Ntla-2002 Shows Promising Results, but Stock Drops Following Phase 2 Data Release
NTLA

GuruFocus.com

6 months ago

Intellia's Ntla-2002 Shows Promising Results, but Stock Drops Following Phase 2 Data Release

NTLA

Investing.com

6 months ago

Intellia Therapeutics stock plunges after phase 2 results from NTLA-2002 study

Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
NTLA

GlobeNewswire

6 months ago

Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

Intellia data spark debate about CRISPR drug’s potential
NTLA

BioPharma Dive

6 months ago

Intellia data spark debate about CRISPR drug’s potential

Share on Social Networks: